Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment

被引:10
|
作者
de Thurah, Annette [1 ,2 ]
Andersen, Ina Trolle [3 ]
Tinggaard, Andreas Bugge [4 ]
Riis, Anders Hammerich [3 ]
Therkildsen, Josephine [4 ]
Botker, Hans Erik [2 ,5 ]
Bottcher, Morthen [4 ]
Hauge, Ellen-Margrethe [1 ,2 ]
机构
[1] Aarhus Univ Hosp Skejby, Dept Rheumatol, Aarhus N, Denmark
[2] Aarhus Univ, Dept Clin Med, Aarhus N, Denmark
[3] Aarhus Univ Hosp Skejby, Dept Clin Epidemiol, Aarhus N, Denmark
[4] Hosp Unit West, Dept Cardiol, Herning, Denmark
[5] Aarhus Univ Hosp Skejby, Dept Cardiol, Aarhus N, Denmark
来源
RMD OPEN | 2020年 / 6卷 / 01期
关键词
COMPOSITE END-POINTS; DISEASE-ACTIVITY; RECOMMENDATIONS; METAANALYSIS; PERFORMANCE; VALIDATION; MORTALITY; REGISTER; SCORE;
D O I
10.1136/rmdopen-2019-001113
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Rheumatoid arthritis (RA) is a known risk factor for developing coronary artery disease (CAD). The influence of RA on the prognosis after initial CAD diagnosis and treatment is however largely unknown. We examined the risk of major cardiovascular events among RA and non-RA patients with chest pain referred to cardiac CT. Methods This was a follow-up study, using data from the Western Denmark Heart Registry, containing data on CT angiography examinations (Cardiac CT). Information on RA diagnosis and covariates were identified through nationwide administrative registers. The primary outcome was a combined outcome including, myocardial infarction, ischaemic or unspecified stroke, coronary artery bypass grafting, percutaneous coronary intervention, and all-cause mortality. Median time until events or censoring was 3.5 years (min/max: 0.0: 9.2). Cox proportional hazard models were used to examine the association between RA/non-RA patients and outcomes. Results Among 42 257 patients, referred between 2008 and 2016, we identified 358 (0.8%) with RA. An increased risk was seen in RA compared with non-RA (adjusted HR 1.35, 95% CI 0.93 to 1.96). Among patients who had received flare treatment more than once prior to cardiac CT the adjusted HR 1.80 (95% CI 1.08 to 3.00), and among patients with seropositive RA the adjusted HR 1.42 (95% CI 0.93 to 2.16). Conclusion In patients referred to cardiac CT due to chest pain, we found a trend of an association between RA and the combined primary outcome, supporting that RA per se, but in particular seropositive and active RA, may increase the risk of CAD even after initial CAD diagnosis and treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
    Mal, Kheraj
    Kumar, Ratan
    Mansoor, Farah
    Kaur, Navneet
    Kumar, Anil
    Memon, Sidra
    Rizwan, Amber
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [2] RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND A LOW-INTERMEDIATE A PRIORI RISK OF CORONARY ARTERY DISEASE AFTER INITIAL CT-BASED DIAGNOSIS AND TREATMENT A REGISTRY-BASED FOLLOW-UP STUDY USING DATA FROM THE WESTERN DENMARK HEART REGISTRY
    de Thurah, Annette
    Andersen, Ina Trolle
    Tinggaard, Andreas Bugge
    Riis, Anders Hammerich
    Therkildsen, Josephine
    Botker, Hans Erik
    Bottcher, Morten
    Hauge, Ellen-Margrethe
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1392 - 1392
  • [3] Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, David
    Giles, Jon T.
    Bathon, Joan M.
    Sattar, Naveed
    Lee, Janet S.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S642 - S642
  • [4] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB
    Rao, Vijay
    Pavlov, Andrey
    Klearman, Micki
    Musselman, Dave
    Giles, Jon
    Bathon, Joan
    Sattar, Naveed
    Lee, Janet
    RHEUMATOLOGY, 2012, 51 : 138 - 138
  • [5] Risk of major adverse cardiovascular events in patients with rheumatoid arthritis using Janus Kinase inhibitors
    You, Seung-Hun
    Cho, Soo-Kyung
    Song, Yeo-Jin
    Sung, Yoon-Kyoung
    Jung, Sun-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 521 - 522
  • [6] RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN A SWISS COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLARTHRITIS
    Lauper, K.
    Chevallier-Ruggeri, P.
    Finckh, A.
    Gabay, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 702 - 703
  • [7] Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
    Peluso, Rosario
    Caso, Francesco
    Tasso, Marco
    Ambrosino, Pasquale
    Di Minno, Matteo Nicola Dario
    Lupoli, Roberta
    Criscuolo, Livio
    Caso, Paolo
    Ursini, Francesco
    Del Puente, Antonio
    Scarpa, Raffaele
    Costa, Luisa
    REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (03) : 199 - 209
  • [8] Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
    Karpouzas, George Athanasios
    Ormseth, Sarah R.
    van Riel, Piet Leonardus Cornelis Maria
    Gonzalez-Gay, Miguel A.
    Corrales, Alfonso
    Rantapaa-Dahlqvist, Solbritt
    Sfikakis, Petros P.
    Dessein, Patrick
    Tsang, Linda
    Hitchon, Carol
    El-Gabalawy, Hani
    Pascual-Ramos, Virginia
    Contreras-Yanez, Irazu
    Colunga-Pedraza, Iris J.
    Galarza-Delgado, Dionicio Angel
    Azpiri-Lopez, Jose Ramon
    Semb, Anne Grete
    Misra, Durga Prasanna
    Hauge, Ellen-Margrethe
    Kitas, George
    RMD OPEN, 2024, 10 (03):
  • [9] Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
    Dougados, Maxime
    Charles-Schoeman, Christina
    Szekanecz, Zoltan
    Giles, Jon T.
    Ytterberg, Steven R.
    Bhatt, Deepak L.
    Koch, Gary G.
    Vranic, Ivana
    Wu, Joseph
    Wang, Cunshan
    Kwok, Kenneth
    Menon, Sujatha
    Connell, Carol A.
    Yndestad, Arne
    Rivas, Jose L.
    Buch, Maya H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 575 - 577
  • [10] IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Dougados, M.
    Charles-Schoeman, C.
    Szekanecz, Z.
    Giles, J. T.
    Ytterberg, S. R.
    Bhatt, D. L.
    Koch, G. G.
    Vranic, I.
    Wu, J.
    Wang, C.
    Kwok, K.
    Menon, S.
    Connell, C. A.
    Yndestad, A.
    Rivas, J. L.
    Buch, M. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 175 - 176